JP7084881B2 - Ｉｌ－１０の免疫刺激特性および抗炎症特性を調節するための組成物および方法 - Google Patents

Ｉｌ－１０の免疫刺激特性および抗炎症特性を調節するための組成物および方法 Download PDF

Info

Publication number
JP7084881B2
JP7084881B2 JP2018566552A JP2018566552A JP7084881B2 JP 7084881 B2 JP7084881 B2 JP 7084881B2 JP 2018566552 A JP2018566552 A JP 2018566552A JP 2018566552 A JP2018566552 A JP 2018566552A JP 7084881 B2 JP7084881 B2 JP 7084881B2
Authority
JP
Japan
Prior art keywords
scil
amino acid
polypeptide
linker
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018566552A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019527200A (ja
JP2019527200A5 (https=
Inventor
ムスターカス、ディミトリ、ティー．
ナムチュク、マーク、エヌ．
ロージー、ヘザー、シー．
アルバレス、ファン、シー．
Original Assignee
アルカームス インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルカームス インコーポレーテッド filed Critical アルカームス インコーポレーテッド
Publication of JP2019527200A publication Critical patent/JP2019527200A/ja
Publication of JP2019527200A5 publication Critical patent/JP2019527200A5/ja
Application granted granted Critical
Publication of JP7084881B2 publication Critical patent/JP7084881B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2018566552A 2016-06-22 2017-06-22 Ｉｌ－１０の免疫刺激特性および抗炎症特性を調節するための組成物および方法 Expired - Fee Related JP7084881B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662353478P 2016-06-22 2016-06-22
US62/353,478 2016-06-22
PCT/US2017/038747 WO2018005226A2 (en) 2016-06-22 2017-06-22 Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties

Publications (3)

Publication Number Publication Date
JP2019527200A JP2019527200A (ja) 2019-09-26
JP2019527200A5 JP2019527200A5 (https=) 2020-07-30
JP7084881B2 true JP7084881B2 (ja) 2022-06-15

Family

ID=60674961

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018566552A Expired - Fee Related JP7084881B2 (ja) 2016-06-22 2017-06-22 Ｉｌ－１０の免疫刺激特性および抗炎症特性を調節するための組成物および方法

Country Status (6)

Country Link
US (2) US10335459B2 (https=)
EP (1) EP3474884A4 (https=)
JP (1) JP7084881B2 (https=)
AU (2) AU2017291321B2 (https=)
CA (1) CA3026393C (https=)
WO (1) WO2018005226A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2616045B1 (en) 2010-09-15 2017-10-25 Randall J. Mrsny Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
PL3139965T3 (pl) 2014-05-07 2022-01-31 Applied Molecular Transport Inc. Cząsteczki fuzyjne pochodzące z toksyny cholix do doustnego dostarczania ładunku biologicznie czynnego
AU2015364396B2 (en) * 2014-12-19 2018-08-09 Alkermes, Inc. Single chain Fc fusion proteins
JP7084881B2 (ja) 2016-06-22 2022-06-15 アルカームス インコーポレーテッド Ｉｌ－１０の免疫刺激特性および抗炎症特性を調節するための組成物および方法
EP3768699B1 (en) * 2018-03-23 2025-11-12 Gavish-Galilee Bio Applications Ltd. Genetically reprogrammed tregs expressing membrane-bound il-10
KR20210110294A (ko) 2018-11-07 2021-09-07 어플라이드 몰레큘라 트랜스포트 인크. 통과세포외배출용 전달 구조체 및 관련 방법
US12006345B2 (en) 2019-02-21 2024-06-11 Xencor, Inc. Untargeted and targeted IL-10 Fc-fusion proteins
CN114599665A (zh) 2019-08-16 2022-06-07 应用分子转运公司 组合物、制剂及白细胞介素产生和纯化
EP3795583A1 (en) * 2019-09-19 2021-03-24 Ecole Polytechnique Federale de Lausanne (EPFL) Il10/fc fusion proteins useful as enhancers of immunotherapies
CN112625137B (zh) * 2019-10-08 2021-10-08 北京东方百泰生物科技股份有限公司 一种人白细胞介素10-Fc融合蛋白及其医药用途
EP4065585B1 (en) 2019-11-25 2025-08-20 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
EP4126017A4 (en) * 2020-04-03 2024-05-22 Baylor College of Medicine Tnf-alpha signaling triggers tumor-promoting inflammation that can be targeted to therapy
MX2022014239A (es) 2020-05-12 2023-02-09 Regeneron Pharma Nuevos agonistas de il10 y metodos para su uso.
KR20230017840A (ko) * 2020-05-28 2023-02-06 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 조작된 인터루킨-10 폴리펩타이드 및 이의 용도
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
WO2024094755A1 (en) * 2022-11-02 2024-05-10 Synerkine Pharma B.V. Engineered immunocytokines, fusion polypeptides, and il10 polypeptides
WO2024131864A1 (zh) * 2022-12-21 2024-06-27 广东菲鹏制药股份有限公司 一种il-10单体融合蛋白
WO2024144336A1 (ko) * 2022-12-30 2024-07-04 주식회사 프로젠 신규 이중 특이성 융합단백질 및 그의 용도
EP4719457A2 (en) * 2023-06-02 2026-04-08 Synthekine, Inc. Fused il10 polypeptides
WO2025247362A1 (zh) * 2024-05-31 2025-12-04 江苏先声生物制药有限公司 抗cdh17抗体、缀合物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130316404A1 (en) 2010-11-26 2013-11-28 The University Of Manchester Covalently linked interleukin-10

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE194384T1 (de) 1989-09-12 2000-07-15 Hoffmann La Roche Tnf-bindende proteine
JP2002530066A (ja) 1998-11-19 2002-09-17 スミスクライン・ビーチャム・コーポレイション Ｒｈａｍｍアンタゴニスト抗体
US6428985B1 (en) * 1998-12-02 2002-08-06 The Regents Of The University Of Michigan Immunosuppressive structural definition of IL-10
ATE407697T1 (de) 1999-07-13 2008-09-15 Bolder Biotechnology Inc Erythropoietin immunglobulin fusionsproteine
EP1257574A1 (en) 2000-02-11 2002-11-20 Maxygen Aps Improved interleukin 10
WO2004044006A1 (en) * 2002-11-14 2004-05-27 Maxygen, Inc. Conjugates of interleukin-10 and polymers
PT1624891E (pt) 2003-05-06 2010-01-05 Syntonix Pharmaceuticals Inc Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia
US7696322B2 (en) 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
US20150071948A1 (en) 2003-09-26 2015-03-12 Gregory Alan Lazar Novel immunoglobulin variants
WO2008140595A2 (en) 2006-12-01 2008-11-20 President And Fellows Of Harvard College Synthetic trivalent haptens, complexes thereof, and uses therefor
AU2010334974A1 (en) 2009-12-22 2012-07-12 Novartis Ag Tetravalent CD47-antibody constant region fusion protein for use in therapy
CN102958942A (zh) 2009-12-29 2013-03-06 新兴产品开发西雅图有限公司 异二聚体结合蛋白及其应用
AR080993A1 (es) 2010-04-02 2012-05-30 Hanmi Holdings Co Ltd Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
AU2011226992B2 (en) 2010-05-10 2012-03-22 Ascend Biopharmaceuticals Pty Ltd Immunostimulatory and vaccine compositions
CN101962413B (zh) 2010-09-21 2013-03-13 中国科学技术大学 具有透皮能力和白细胞介素-10活性的融合蛋白及其编码基因与应用
KR101333958B1 (ko) 2010-10-20 2013-11-27 주식회사 한독 인간 인터루킨-1 수용체 길항제-하이브리드 Ｆｃ 융합단백질
TWI588156B (zh) 2011-03-28 2017-06-21 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
EP2723380B1 (en) 2011-06-24 2019-08-21 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
MY169358A (en) 2011-08-23 2019-03-26 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
US9062120B2 (en) 2012-05-02 2015-06-23 Janssen Biotech, Inc. Binding proteins having tethered light chains
RS61391B1 (sr) * 2012-06-08 2021-02-26 Alkermes Pharma Ireland Ltd Ligandi modifikovani primenom cirkularnog permutiranja kao agonisti i antagonisti
US20140072581A1 (en) 2012-07-23 2014-03-13 Zymeworks Inc. Immunoglobulin Constructs Comprising Selective Pairing of the Light and Heavy Chains
CA2876285A1 (en) * 2012-08-08 2014-02-13 Roche Glycart Ag Interleukin-10 fusion proteins and uses thereof
AU2014236769B2 (en) 2013-03-15 2018-09-27 Amgen Inc. Heterodimeric bispecific antibodies
US20160068583A1 (en) * 2013-04-24 2016-03-10 Armo Biosciences, Inc. Interleukin-10 Compositions and Uses Thereof
SG11201600734YA (en) * 2013-07-31 2016-02-26 Amgen Inc Stabilization of fc-containing polypeptides
WO2015117930A1 (en) 2014-02-06 2015-08-13 F. Hoffmann-La Roche Ag Interleukine 10 immunoconjugates
CN104403004B (zh) 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
AU2015364396B2 (en) 2014-12-19 2018-08-09 Alkermes, Inc. Single chain Fc fusion proteins
WO2017165464A1 (en) 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
JP7084881B2 (ja) 2016-06-22 2022-06-15 アルカームス インコーポレーテッド Ｉｌ－１０の免疫刺激特性および抗炎症特性を調節するための組成物および方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130316404A1 (en) 2010-11-26 2013-11-28 The University Of Manchester Covalently linked interleukin-10

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J Biol Chem，2006年，Vol.281, No.46，pp.35088-35096
J Exp Med，2000年，Vol.191, No. 2，pp.213-223

Also Published As

Publication number Publication date
CA3026393A1 (en) 2018-01-04
WO2018005226A3 (en) 2018-04-05
AU2020204457A1 (en) 2020-07-23
JP2019527200A (ja) 2019-09-26
WO2018005226A2 (en) 2018-01-04
US20190336582A1 (en) 2019-11-07
US11534480B2 (en) 2022-12-27
EP3474884A4 (en) 2020-08-19
CA3026393C (en) 2023-03-14
US10335459B2 (en) 2019-07-02
AU2017291321B2 (en) 2020-06-18
EP3474884A2 (en) 2019-05-01
US20170368144A1 (en) 2017-12-28
AU2017291321A1 (en) 2018-12-13
NZ748787A (en) 2021-06-25

Similar Documents

Publication Publication Date Title
JP7084881B2 (ja) Ｉｌ－１０の免疫刺激特性および抗炎症特性を調節するための組成物および方法
US10881741B2 (en) Single chain Fc fusion proteins
US20240368236A1 (en) Growth differentiation factor 15 (gdf-15) constructs
ES2689762T3 (es) Proteínas de fusión para el tratamiento de trastornos metabólicos
JP7064618B2 (ja) 増殖分化因子１５アゴニスト化合物およびその使用方法
JP7058670B2 (ja) 増殖分化因子１５融合タンパク質
ES2966133T3 (es) Proteína de fusión que comprende el factor de crecimiento nervioso y método de preparación y uso de la misma
JP7013390B2 (ja) Ｍｉｃ－１化合物及びその使用
KR20210065057A (ko) 지속형 gdf15 융합 단백질 및 이를 포함하는 약학 조성물
WO2022187488A2 (en) Mutant pd-1 extracellular domains
NZ748787B2 (en) Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties
JP2025539794A (ja) 二重機能タンパク質およびその使用
HK1242337B (en) Single chain fc fusion proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200616

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210615

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210915

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211214

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220510

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220603

R150 Certificate of patent or registration of utility model

Ref document number: 7084881

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees